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Introduction. Pulmonary arterial hypertension (PAH) is a rare disease that must be managed in specialized centers; therefore,
the availability of epidemiological national data is critical. Methods. We conducted a prospective, observational, and multicenter
registry with a joint collaboration from five centers from Portugal and included adult incident patients with PAH or chronic
thromboembolic pulmonary hypertension (CTEPH). Results. Of the 79 patients enrolled in this study, 46 (58.2%) were classified as
PAH and 33 patients (41.8%) as CTEPH. PAH patients had a mean age of 43.4 ± 16.4 years. Idiopathic PAH was the most common
etiology (37%). At presentation, PAH patients had elevated right atrial pressure (RAP) (7.7 ± 5.9mmHg) and mean pulmonary
vascular resistance (11.4 ± 6.5 Wood units), with a low cardiac index (2.7 ± 1.1 L⋅min−1⋅m−2); no patient was under selective
pulmonary vasodilators; however, at follow-up, most patients were on single (50%), double (28%), or triple (9%) combination
vasodilator therapy. One-year survival was 93.5%, similar to CTEPH patients (93.9%), that were older (60.0 ± 12.5 years) and
had higher RAP (11.0 ± 5.2mmHg, 𝑃 = 0.015). Conclusions. We describe for the first time nationwide data on the diagnosis,
management, and prognosis of PAH and CTEPH patients in Portugal. Clinical presentation and outcomes are comparable with
those reported on other national registries.
1. Introduction
In the past few decades, the international scientific com-
munity has made great progresses in the understanding
of the epidemiology, pathophysiology, and management of
pulmonary arterial hypertension (PAH). It is a rare disease,
malignant in character, and rapidly fatal, if not treated,
with a median survival of 2.8 years in a historic cohort [1].
These progresses were accompanied by the development of
drugs that target specific pathways in the pathophysiology
of the disease [2]. Management in specialized centers and
the use of pulmonary vasodilators lead to a significant
impact on the survival and quality of life of PAH patients
[3]. Unfortunately, survival rates are still unsatisfactory [4],
signaling for the need of more effective treatments, which are
under development [5].
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Since the first consensus conference in 1973 [6], the
classification of pulmonary hypertension (PH) has evolved,
reflecting the ongoing understanding of the condition, and
now it includes five groups with several subtypes [7]. Within
group 1 PH, an idiopathic subgroup is maintained, high-
lighting that there is still a lot to understand about the
pathogenesis of the disease. The diagnostic and therapeutic
approach should be guided by national and international
guidelines supported by scientific societies, and given the
rarity and severity of the disease, its proper investigation and
treatment should be performed in expert centers [8, 9].
Chronic thromboembolic pulmonary hypertension
(CTEPH), classified as group 4 PH, has a different patho-
physiology and treatment from other PH groups. Pulmonary
endarterectomy (PEA) is a potentially curative procedure for
CTEPH [10]. For those patients not eligible for surgery or
those with persistent PH after PEA, specific treatment may
ameliorate symptoms and enhance survival [9, 11].
The organization and publication of national and inter-
national registries are essential in the understanding of the
epidemiology, etiology, and natural history of the different
groups of PH [3]. Several groups have published data from
their cohorts [12–17], although with different inclusion and
exclusion criteria and methodologies [16]; to overcome these
disparities, the creation of an international registry has been
suggested [18]. Moreover, it is unclear if data from regional
registries can be applied to other populations [13]. Data
from national registries are not a surrogate for application
in other countries and cannot be easily extrapolated due
to demography, treatment availability, and other regional
differences. Therefore, national registries from each region
are paramount in the interpretation of the applicability of
international recommendations, which are issued regardless
of those differences. Our aim is to present data from a
Portuguese registry of patients with group 1 and group 4 PH
and to compare them with other published cohorts.
2. Population and Methods
We conducted a prospective, observational, and multicen-
ter registry with a joint collaboration from five PH cen-
ters around Portugal. Although there are small differences
between the institutions regarding patient follow-up, all of
them follow similar protocols, according to the published
national [8] and international [19] guidelines. Our study
population consisted of adult incident PH patients referred
to those centers for diagnostic and therapeutic evaluation,
between 2008 and 2010. Data were collected by clinical file
review by a physician, with supervision from the assistant
PH physician, and were compiled in a dedicated software,
specifically developed for the management of PH patients
(PAHTool, Inovultus, Santa Maria da Feira, Portugal), cre-
ating a database and the backbone for a national registry.
An informed consent was obtained from each patient, and
the study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki as reflected in a priori
approval by the institution’s human research committee. The
centers’ participation in this registry was voluntary, and
the nationwide data collection was approved by the National
Center for Data Protection.
To enable comparisonswith other published registries, we
used strict inclusion and exclusion criteria. All patients had
PAH confirmed by right heart catheterization (RHC), with
a mean pulmonary arterial pressure (PAP) over 25mmHg
and a pulmonary wedge pressure (PCWP) equal or under
15mmHg or a left ventricular end diastolic pressure (LVEDP)
equal or under 15mmHg. The date of diagnosis corresponds
to the confirmation of PAH by RHC.
Studied data included demographic characteristics, clin-
ical and laboratorial parameters, World Health Organization
(WHO) functional class, haemodynamics, and conventional
and specific vasodilator therapy usage and survival status.
Vasoreactivity testing was performed when possible, using
various institutional protocols. A one-year follow-up was
conducted; no patients were lost to follow-up.
All results are expressed as themean± standard deviation
or as the frequency.WeusedKolmogorov-Smirnov for testing
normality, Student’s 𝑡-test for continuous variables, and 𝑋2-
test for categorical variables. Survival analysis was performed
using theKaplan-Meiermethod, and comparisonsweremade
using the Log-Rank test. Values of 𝑃 < 0.05 were considered
to be significant. Statistical analysis was performed using
SPSS 17.0 software package (IBM, New York, USA).
3. Results
Our registry originally included 188 PH patients (Figure 1).
After exclusion of 79 patients from groups 2, 3, and 5 PH, 134
patients were left for analysis. Thirty patients were excluded
as they did not have an available RHC. The final analysis
included 79 patients. Of the 79 patients enrolled in this study,
46 (58.2%) patients were classified as PAH and 33 patients
(41.8%) as CTEPH.
3.1. Demographics and Clinical Data. There was a clear pre-
ponderance of women among PAH patients, with a female/
male patient ratio of 1.9 : 1. Mean age at diagnosis was 43.4 ±
16.4 years (range, 15 to 77 years) (Table 1). There was no
difference among genders regarding age at first medical
examination (𝑃 = 0.963). Among the 46 patients, 9.2% (𝑛 =
11) were <21 years old, 58.3% (𝑛 = 21) were 21 to 40 years
old, 32.6% (𝑛 = 15) were 40 to 59 years old, and 17.4% (𝑛 = 8)
were > 61 years old. Patients between 21 and 60 years of age
accounted for 87% of all patients.
Idiopathic PAHwas present in 17 (37%) patients, followed
by connective tissue disease (CTD) (𝑛 = 12, 26%), congenital
heart disease (CHD) (𝑛 = 10, 22%), portopulmonary hyper-
tension (𝑛 = 5, 11%), familial (𝑛 = 1, 2%), and other etiologies
(𝑛 = 1, 2%) (Table 2). At baseline, most patients presented in
WHO class III or IV (71%); only one patient was in class I.
CTEPH patients had a higher mean age at diagnosis
(60.3 ± 12.5, 𝑃 < 0.001) than group 1 PAH patients; a
significant proportion of the population had more than 51
years at diagnosis (63.6%) (Figure 2). Both WHO class at
presentation and the female/male ratio were similar to group
1 PAH patients.
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PH incident registry
2008–2010
188 PH patients
Included in the analysis (n = 79)
- PAH patients (n = 46)
- CTEPH patients (n = 33)
Excluded (n = 54)
- Group 2 PH (n = 34)
- Group 3 PH (n = 15)
- Group 5 PH (n = 5)
Excluded (n = 55)
- No available RHC (n = 30)
- PCWP over 15mmHg (n = 25)
Figure 1: Patient selection flowchart.
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Figure 2: Distribution of age and gender.
3.2. Hemodynamics. RHC was performed in all patients at
the initial examination (Table 1). Baseline data shows that
in group 1 PAH patients, mean RAP was 7.7 ± 5.9mmHg,
mean PAP was 50.6 ± 17.9mmHg, and mean PCWP was
9.5 ± 3.5mmHg; PVR was 11.4 ± 6.5 Wood units. Mean
cardiac output (CO) was 4.5 ± 1.8 L⋅min−1, and mean cardiac
index (CI) was 2.7 ± 1.1 L⋅min−1⋅m−2. Cardiac output was
more elevated in WHO class I/II than in the WHO class III
or IV patients, but it did not reach statistical significance.
Conversely, PVR was higher in patients in WHO class III/IV
than patients in WHO class I/II (Table 3). Vasoreactivity
testing was performed in 29 (63.0%) patients with various
protocols; 6 patients (21%) had a positive test.
Regarding CTEPH, the only hemodynamic parameter at
the time of diagnostic RHC that was significantly different
from PAH was the mean RAP (11.0 ± 5.2mmHg, 𝑃 = 0.015),
that was significantly higher.
3.3. Treatment. Drug therapy at study inclusion is shown
in Table 4. At baseline, all PAH patients were treated only
with conventional therapy. Diuretics were used by 15 patients
(32.6%), followed by oxygen in 9 patients (19.6%) and
digoxin in 7 patients (15.2%). At follow-up, 42 patients
were treated with advanced PAH therapies and 40 with
pulmonary vasodilators, and two patients were enrolled in
randomized controlled trials (RCT) (Table 5). Most patients
were medicated with endothelin receptor antagonists (𝑛 =
33), followed by phosphodiesterase inhibitors (𝑛 = 26) and
prostanoids (𝑛 = 4). Thirteen patients (28%) were under
double combination therapy and 4 (9%) patients under triple
combination therapy.
No differences were found regarding baseline treatment
modalities among PAH and CTEPH patients. However,
during follow-up, targeted therapies were begun in 67% of
CTEPH patients, and 5 patients (15.2%) had a PEA. Com-
bination therapy was offered to 9 CTEPH patients during
the follow-up period. Endothelin receptor antagonists were
used in 17 patients, followed by sildenafil in 13 patients and
prostanoids in 2 patients. One patient was enrolled in a RCT.
3.4. One-Year Survival Analysis. Survival data was available
for all patients (Figure 3). One year after the diagnostic
RHC, 5 patients were deceased. The Kaplan-Meier survival
estimates for patients with PAH and CTEPH at 1 year
were 93.5% and 93.9%, respectively (Log-rank 𝑃 = 0.709).
Unoperated CTEPH patients had a one-year survival rate of
92.9%, whereas all patients that underwent PEA survived.
3.5. Comparisonwith theCohort of Group 1 PAHPatients with-
out Available Baseline RHC. The original database included
4 BioMed Research International
Table 1: Demographic, clinical, and hemodynamic characteristics of pulmonary arterial hypertension (PAH) and chronic thromboembolic
pulmonary hypertension (CTEPH) incident patients at baseline.
Total (𝑛 = 79) PAH (𝑛 = 46) CTEPH (𝑛 = 33) 𝑃 value
Age (years) 50.5 ± 17.0 43.4 ± 16.4 60.3 ± 12.5 <0.001
Female gender, 𝑛 (%) 53 (67.1%) 30 (65.2%) 23 (69.7%) 0.676
Six-minute test walking distance (m) 351.3 ± 137.4 370.8 ± 140.1 320.4 ± 132.9 0.327
Functional class, 𝑛 (%)
I 1 (1%) 1 (2%) 0 (0%) 0.565
II 17 (25%) 11 (27%) 6 (21%)
III 34 (49%) 21 (51%) 13 (46%)
IV 17 (25%) 8 (20%) 9 (32%)
Hemodynamic data
Right atrial pressure (mmHg) 9.1 ± 5.8 7.7 ± 5.9 11.0 ± 5.2 0.015
Mean pulmonary artery pressure (mmHg) 49.1 ± 15.1 50.6 ± 17.9 47.1 ± 9.9 0.313
Cardiac output (L⋅min−1) 4.4 ± 1.9 4.5 ± 1.8 4.3 ± 2 0.778
Cardiac index (L⋅min−1⋅m−2) 2.6 ± 1.1 2.7 ± 1.1 2.5 ± 1.1 0.406
Pulmonary capillary wedge pressure (mmHg) 9.7 ± 3.3 9.5 ± 3.5 9.9 ± 3.1 0.587
Pulmonary vascular resistance (Wood units) 11.1 ± 6.4 11.4 ± 6.5 10.8 ± 6.3 0.729
Table 2: Clinical and hemodynamic data stratified by pulmonary arterial hypertension subgroup.
Subgroup 𝑁 (%) Female (%) Age(years)
WHO I/II
(%)
6MWT
(meters)
RAP
(mmHg)
mPAP
(mmHg)
CO
(L⋅min−1)
PCW
(mmHg)
PVR
(WU)
Idiopathic 17 (37.0) 70.6 37.5 ± 12.9 31.3 405 ± 121 11 ± 6 53 ± 15 4.2 ± 1.5 10.7 ± 3.3 11.7 ± 5.6
CTD 12 (26.1) 75.0 56.8 ± 12.4 27.3 275 ± 127 6 ± 6 39 ± 11 4.9 ± 1.8 7.6 ± 3.2 8.7 ± 7
CHD 10 (21.7) 50.0 37.7 ± 15 22.2 351 ± 171 6 ± 5 60 ± 27 4.6 ± 2.7 10.7 ± 3.7 13.9 ± 8.9
PortPulm 5 (10.9) 60.0 51.2 ± 18.3 33.3 n/d 7 ± 5 51 ± 11 4 ± 1.2 8.6 ± 2.9 11.1 ± 3.3
Total 44 (100.0)∗ 65.2 43.4 ± 16.4 29.3 371 ± 140 8 ± 6 51 ± 18 4.5 ± 1.8 9.5 ± 3.5 11.4 ± 6.5
CTD: connective tissue disease; CHD: congenital heart disease; PortPulm: portopulmonary. WHO: World Health Organization; 6MWT: six-minute walking
test distance; RAP: right atrial pressure; mPAPA: mean pulmonary artery pressure; CO: cardiac output; PCWP: pulmonary capillary wedge pressure; PVR:
pulmonary vascular resistance; WU: wood units.
∗Heritable PAH (𝑛 = 1) and other etiologies PAH (𝑛 = 1) were not reported as there was one case of each in the cohort.
Table 3: Hemodynamic characteristics stratified by NYHA class of pulmonary arterial hypertension incident patients.
(𝑛 = 46) NYHA I/II NYHA III NYHA IV 𝑃 value
Six-minute walk test distance (m) 436 ± 147 356 ± 106 236 ± 128 0.094
Female gender 67.8% 71.4% 37.5% 0.229
Right atrial pressure (mmHg) 8 ± 6 8 ± 6 7 ± 7 0.854
Mean pulmonary artery pressure (mmHg) 54 ± 26 49 ± 11 45 ± 13 0.492
Pulmonary capillary wedge pressure (mmHg) 9 ± 3 10 ± 4 7 ± 3 0.092
Cardiac output (L⋅min−1) 5.4 ± 0.9 4.6 ± 2.1 3.2 ± 1.6 0.097
Pulmonary vascular resistance (Wood units) 9.1 ± 4.6 10.6 ± 5.6 15.3 ± 6.1 0.123
Table 4: Conventional therapies at baseline and follow-up of pulmonary arterial hypertension (PAH) and chronic thromboembolic
pulmonary hypertension (CTEPH) patients.
Total PAH CTEPH
Baseline Follow-up Baseline Follow-up Baseline Follow-up
Diuretics 33 (41.8%) 40 (65.6%) 15 (32.6%) 17 (60.7%) 18 (54.5%) 23 (69.7%)
Digoxin 13 (16.5%) 18 (2.8%) 7 (15.2%) 11 (23.9%) 6 (18.2%) 7 (21.2%)
Oxygen 21 (26.6%) 25 (31.6%) 9 (19.6%) 12 (26.1%) 12 (36.4%) 13 (39.4%)
Warfarin 34 (43.0%) 59 (74.7%)∗ 10 (21.7%) 28 (60.9%)∗ 24 (72.7%) 31 (93.9%)∗
∗
𝑃 < 0.001 versus baseline.
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Figure 3: One-year survival in pulmonary arterial hypertension (a) and chronic thromboembolic pulmonary hypertension (b) patients.
Table 5: Pulmonary vasodilator therapies at follow-up of pul-
monary arterial hypertension (PAH) and chronic thromboembolic
pulmonary hypertension (CTEPH) patients.
PAH CTEPH
No advanced therapies 2% 33%
Single therapy 50% 36%
Double combination therapy 28% 15%
Triple combination therapy 9% 7%
Calcium channel blockers 7% 0%
Randomized controlled trial drug 4% 3%
20 patients classified as PAHbut without an available baseline
RHC; therefore, they were not included in the analysis. This
may have been due to the incomplete filling of the database
fields and thus not necessarily reflecting the absence of
RHC. Comparing with included PAH patients, we found no
significant differences regarding gender, age, orWHO class at
presentation of these patients. Although not reaching statis-
tical significance, there was a trend for a higher proportion of
patients with CHD-associated PAH in the group of patients
that did not had a RHC. No survival differences were found
among the two groups.
3.6. Estimated Incidence of PAH and CTEPH. Although
limited by the voluntary collection of data and by the selective
inclusion and exclusion criteria, we identified 46 patients
with incident group 1 PAH and 33 patients with CTEPH
during the 3-year follow-up period. For a population of 10
million inhabitants in Portugal, we calculated a conservative
estimation of group 1and group 4 PH annual incidence of at
least 1.5 and 1.1 patients per million, respectively. However, if
we include patients with a clinical diagnosis of group 1 PAH
but without an available RHC, our incidence would rise to 2.2
per million per year.
4. Discussion
The present study summarizes data representative of the
Portuguese PH cohort. With the combined effort of five
treatment centers, we were able for the first time to collect
nationwide data on the diagnosis, management, and clinical
course of PAH and CTEPH in Portugal.
To analyze a homogeneous population and to enable
comparisons with other published cohorts [12, 17, 20], we
followed strict inclusion and exclusion criteria based on
current guidelines [9]. We focused only on PAH and CTEPH
patients, as the prevalence and clinical characteristics of
group 2 and group 3 PH varied widely among the five
PH centers. Additionally, we included only incident cases
to remove survivor bias from our study and to permit an
approximate calculation of annual incidence, as prevalent
cases correspond mainly to survivors [12].
In our PAH population, age at diagnosis was lower than
in the REVEAL [20] and French [12] cohorts but higher than
in the NIH registry [21]. This may be due to the fact that
one-fifth of our patients had CHD-associated PAH; these
patients were excluded from the French registry [12] but not
from the REVEAL cohort [20]. Other important aspect is that
almost 20% of PAH patients were over 60 years, a finding that
is being increasingly recognized in contemporary registries.
CTEPH patients were older, with a mean age at diagnosis of
60 years, similar to the one found in the Swiss cohort [22] and
the randomized clinical trial [23]. Interestingly, our CTEPH
population was significantly older than a published cohort
of patients developing CTEPH after an acute pulmonary
embolism [24]. This fact may warrant further investigation
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andmay signalize a different epidemiology of postpulmonary
embolism CTEPH.
Possibly due to the fact that we have no patients with PAH
secondary to anorexigens, a group almost exclusively formed
by women [25], the proportion of female patients (65%)
in our PAH cohort was lower than that in most published
reports [26].
Idiopathic PAH was the most frequent subgroup of PAH,
with a proportion of 37%, similar to the French cohort
(41% in the incident cohort) [12] but lower than in the
REVEAL cohort (47%) [20]. CTD-PAHwas the second most
common cause, with 26%, a number that is higher than
that reported on the French (18%) [12] but similar to the
REVEAL cohort (24%) [20]. Systemic sclerosis is the leading
cause of CTD-PAH, with 8% of patients developing this
dismal prognostic finding in the course of their disease [27];
echocardiographic screening may be of value and has a grade
IIb C recommendation on the current ESC guidelines [9].
As expected, patients with CHD-PAH were frequent in
our series (22%), a significantly higher proportion than in
the French and REVEAL cohorts [12, 20]. This may be the
result of the poor access of CHD patients to corrective heart
surgery in the appropriate age; however, CHD patients are
also clearly underrepresented in other epidemiological series,
as in the French cohort due to health organization issues [12].
Portopulmonary hypertension had a similar incidence to the
French series.
PAH baseline haemodynamics was similar to those from
the NIH, REVEAL French Comparison Cohort (FCC), and
French registry. The mean PAP was 51mmHg, being essen-
tially the same of the French registry (55mmHg) [12] and
the REVEAL FCC (51mmHg) [26] and slightly lower than
the NIH cohort (60mmHg) [1]. Mean RAP at diagnosis was
8mmHg, the same as the French (8mmHg) and REVEAL
FCC registry (8mmHg).
Most PAH patients presented to the referral center with
symptoms of advanced heart failure. In 71% of cases, they
were in WHO class III or IV, similarly to the REVEAL FCC
(73%) [26] and the French registry (75%) [12]. This number
is even more dramatic as it is similar to the one reported on
the 20-year-old NIH cohort (71%) [21]. The combination of
high RAP with an advanced functional class on presentation
signalizes that more effort is needed for early identification
and referral of patients to expert centers, as there is evidence
that treating patients in WHO class II has a positive impact
on patients’ outcomes [28].
CTEPH patients had similar haemodynamics compared
to PAH, except for mean RAP, which was significantly higher.
This finding that was not reproduced in the Swiss cohort [22],
is higher than that reported in the BENEFIT study [23] and
in the Cambridge cohort [29]. Higher right ventricular filling
pressures were accompanied by a higher number of patients
being referred toWHOclass III or IV (78%), although similar
to the proportion reported in the literature [29]. This may
indicate late identification and the referral of these potentially
curable patients.
Although having high WHO functional class at presen-
tation, most PAH patients were not treated with diuretics
when referred to the expert centers. The same was true
regarding CTEPH patients; however, there was a trend for
more intense anticongestive medication in this group. Our
results are comparable to those from the Swiss registry
[22]. Late referral to specialized centers may be in part
due to the lack of an nationwide reference network and
availability of oral vasodilator drugs for PAH treatment, as
less specialized centers may delay transfer patients to expert
centers [12]. In our population, no patient was treated with
specific pulmonary vasodilators before being referred to the
specialized centers.
Vasoreactivity testing was held in 29 of 46 PAH patients
(63%) and was positive in 6 patients (21%). This value is
significantly higher than that reported by the French cohort
(10.3%) [12] but similar to the Swiss registry (20%) [17],
although the latter included 8CTEPHpatients. Selection bias,
differences in the definition of acute responders and in the
treatment protocols used nationwide, may be responsible for
the inconsistencies. Publication of national guidelines may
help to standardize the care for this group of patients.
The progress in prognosis is inseparable from the
advances in pulmonary vasodilator therapy. There are three
classes of selective vasodilator drugs that target three critical
pathways in PAH (prostacyclin, nitric oxide, and endothelin-
1) [2], all being available in Portugal. All of them have their
efficacy demonstrated in several randomized controlled trials
regarding functional capacity, exercise tolerance, haemody-
namics, and other endpoints [30]. Moreover, a recent meta-
analysis confirmed the impact of pulmonary vasodilators on
short-term survival [11]. Overall, in our cohort the one-year
survival for PAH patients was 93.5%, similar to the REVEAL
(91.0%) [20] and the Swiss cohort (89.0%) [22] but higher
than the French cohort (85.7%) [12]. The differences may be
accounted by the small number of events in our cohort (5
deaths) and the relative higher proportion of patients with
CHD-associated PAH (21.7%) compared with the REVEAL
(11.8%), Swiss (approximately 14.3%), and French cohorts
(0%) [12, 17, 20].These patients clearly have a better prognosis
[31], and thus they may have contributed to the positive
survival results.
CTEPH patients had a similar one-year survival (93.9%);
only five patients underwent PEA, a potentially curative
procedure that probably had impact on prognosis, as no
patient died on follow-up. All CTEPH patients are assessed
by the local medical PH team, and the potential surgical
candidates are discussed directly with the foreign referral
center, as the procedure was not routinely performed in
our country. Not operated patients had a survival of 92.9%.
For these patients and for those with residual PH after
PEA, pulmonary vasodilator drug therapy is a class IIb C
recommendation in the ESC guidelines [9]. In our cohort,
two thirds of CTEPH patients started specific therapy, a
number that is comparable to other series [29]. Interestingly,
the one-year survival of the not operatedCTEPHpatientswas
similar to that recently reported in the literature (96%) [32].
Our estimated PAH annual incidence between 1.5 and 2.2
cases per million inhabitants is in line with the published
incidences in other countries: Belgium (1.7 per million) [33],
Israel (1.4 per million) [34], France (2.4 per million) [12],
Switzerland (2.4 per million) [17], and USA (2.0 per million)
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[26]. The wide range between the most conservative estimate
and the higher value is also observed in other series, as in
France, where there are very high regional differences in
PAH prevalence, ranging from 5 to 25 per million inhabitants
per year [12]. CTEPH had, in our population, an estimated
incidence of 1.1 cases per million, a number similar to that
reported in the United Kingdom in 2001 (1.02 cases per
million) but lower than that in 2005 (1.75 cases per million)
[29].
Our study has several limitations. First, although we
included data from five expert PH centers in Portugal, there
are patients followed in other hospitals across the country.
This had impact on incidence calculations, namely, an under-
estimation of values, both in PAH and CTEPH. Second, we
used strict inclusion and exclusion criteria for the recruit-
ment of patients in this registry to ensure a homogenous
population. This has caused the exclusion of all patients
without a RHC on the databases, whether or not there was
one available on the clinical files. However, as our mean
hemodynamic values, demographics, and functional class
data are in line with those published on the literature, we
believe that our population is representative and has external
validity. Thirdly, we decided not to include groups 2, 3, and 5
patients, as there were significant differences among centers
regarding the clinical characteristics of these patients. A
careful analysis was made, but avoiding confounding factors
that are frequent in observational studies may have been
impossible [35].
In conclusion, the present unique study reports for the
first time data on the epidemiology, clinical characteristics,
and prognosis of PAH and CTEPH patients in Portugal.
We conclude that overall PAH incidence is similar to that
reported in other European series, but patients are still being
diagnosed late in the course of their disease. We also report
that CHD-PAH is an important etiology in our country and
may need special attention. The one-year survival analysis of
our incident cohort exceeds 93%, a value that reflects access to
contemporary treatment of PAH, being a strong incentive to
the continuous work being developed by all the community
members involved in this disease. We demonstrated that a
combined and organized registry is possible and is a useful
tool to obtain quality data for clinical decision-making that
compares well with data from other registries. Our findings
encourage the amplification andmaintenance of a nationwide
registry by the combined effort of all the physicians caring
these patients, aiming for a better care and prognosis of PH
patients.
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